BACKGROUND: Data about anticoagulation in pulmonary arterial hypertension (PAH) patients are inconsistent. The objective of this study was to examine the impact of adjunctive oral anticoagulants in patients with PAH through meta-analysis, and to further assess whether response differs by PAH subtype.
P
ulmonary arterial hypertension (PAH) leads to progressive right heart failure and death if untreated. Current classification of PAH includes 4 major subtypes: idiopathic PAH (IPAH), hereditary, that associated with a condition (including connective tissue disease [CTD] , portal hypertension, and congenital heart disease), and drug/toxin mediated. [1] [2] [3] Available therapies for PAH include supportive care with supplemental oxygen and diuretics as necessary, and at least 13 Food and Drug Administration-approved advanced medical therapies targeting 3 major pathways. 3 Despite the latter agents, mortality at 5 years remains ≈40%, leaving considerable room for improvement. 4 Although the advanced therapies have modest effects on endothelial cell function and smooth muscle cell proliferation and hypertrophy, they do not seem to directly target integral aspects of thrombotic pulmonary vascular lesions, which may play a role in the progression of PAH. Moreover, thrombin is a potent growth factor and mitogen, and this may also contribute to disease progression. 5 Thus, a role for anticoagulants in the treatment regimen of PAH patients seems plausible.
Despite a mechanistic basis for warfarin use in PAH, evidence to date has been retrospective, mostly from small single-center studies and with an absence of placebo-controlled randomized studies. 6 Furthermore, discrepancies exist in several important details, including intensity of anticoagulation, patient selection, risk stratification for bleeding, and the appropriateness of anticoagulation based on subtype of PAH. Despite the lack of conclusive evidence, current guidelines recommend warfarin with a goal international normalized ratio of 1.5 to 2.5 for IPAH, heritable PAH, and drug-induced PAH (class IIb recommendation). 7 Anticoagulation is also recommended for patients with associated forms of PAH, including scleroderma-associated PAH (SSc-PAH; class IIb recommendation); however, because of lack of strong evidence, the recommendation is based mostly on consensus opinion. 8 To help reconcile the variable results and limitations of existing studies in this space, we pooled data from all available original studies in the area. We aimed to answer the following question: Does the addition of anticoagulation to the treatment regimen of PAH patients affect survival? Furthermore, we sought to assess whether the effect of anticoagulation varies with the subtype of PAH.
METHODS

Data Sources and Search Strategy
The data, analytic methods, and study materials used in this study are available within this article for purposes of reproducing the results or replicating the procedure. This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic review and Meta-Analyses (PRISMA) guidelines 9 and conducted after guidance from the Cochrane collaboration. 10 Institutional Board Review approval was waived for this article as it is a review of publicly available data. Cochrane CENTRAL, Medline, Scopus, and clinicaltrials.gov were searched from inception until December 2017. Detailed search strategies for each database are provided in the Data Supplement. Other data sources included bibliographies of relevant reviews, including articles and editorials from major medical journals. We also searched websites of major cardiology journals for published conference abstracts, and a nonsystematic search of Google Scholar was also employed to locate indexed abstracts.
Study Selection
All cohort studies (whether prospective or retrospective) and randomized control trials that assessed the association between anticoagulation and outcomes in patients with PAH were considered eligible for our study. We defined anticoagulation as chronic treatment with oral anticoagulants (vitamin K antagonist or novel oral anticoagulants). Studies that did not indicate the type of oral anticoagulant were also considered. Eligible studies had to compare anticoagulants with placebo or no treatment. There were no restrictions on comorbidities, sample size, or follow-up duration. We considered published and unpublished full texts and abstracts. Non-English studies were evaluated with the help of translators. All articles retrieved from the systematic search were exported to Endnote X7 (Clarivate Analytics, PA) and duplicates were removed. Two reviewers (Drs Siddiqi and Usman) independently screened all remaining articles, selecting only those that strictly met the eligibility criteria. A third reviewer (Dr Khan) was consulted in case of discrepancies. Relevant
WHAT IS KNOWN
• Pulmonary arterial hypertension (PAH) remains a challenging disease to manage and continues to have a high mortality rate, despite medical advances.
• The use of anticoagulants in PAH patients is controversial, with individual studies yielding conflicting results.
• Current guidelines cautiously recommend anticoagulation in all PAH patients, regardless of type of PAH; however, this recommendation is based on limited evidence.
• Current evidence about the effect of anticoagulation on mortality in PAH patients is derived only from observational studies, with no published or ongoing clinical trials.
WHAT THE STUDY ADDS
• The present meta-analysis shows that (1) anticoagulation is associated with reduced mortality in all comers with PAH and (2) anticoagulation may be associated with improved survival in idiopathic PAH but may be associated with reduced survival in systemic sclerosis-associated PAH.
• There exists a strong need for a prospective, randomized clinical trial of anticoagulation in PAH articles were initially short-listed based on title and abstract, after which the full text was read to assess relevance.
Data Extraction and Ascertainment of the Risk of Bias
All data from studies were extracted by 2 independent reviewers (Drs Usman and Siddiqi) onto prespecified forms. Timeadjusted mortality was the main outcome. Hazard ratio (HR) and the 95% CI were extracted from each study. We selected HR as an effect estimate, as it adjusts for time, allowing comparison across studies with different lengths of follow-up.
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Estimates adjusted for multiple variables were preferred over unadjusted estimates. On only one occasion, when the HR was not available, we calculated the risk ratio from the number of events and sample size. We also extracted baseline information of the participants, sample size, and follow-up duration. Risk of bias of the included retrospective and prospective cohort studies was assessed using the Newcastle-Ottawa scale (NOS). 12 This was performed by 2 independent reviewers (Drs Siddiqi and Usman), and a third (Dr Khan) who was consulted to settle discrepancies. We did not use the aggregate score of the tool; rather, we made a judgement about the risk of bias using the 2 most important items in the tool (comparability of the 2 study arms and ascertainment of PAH).
The certainty of evidence was determined using the Grading of Recommendations, Assessment, Development, and Evaluation approach. 
Statistical Analysis
Review Manager (Version 5.3; The Cochrane Collaboration; London, United Kingdom) was used to perform the meta-analysis. HRs and their 95% CIs from individual studies were converted to log HRs and corresponding SEs, which were then pooled using a random effects model. The random effects model was selected for meta-analysis because of the observed heterogeneity of study settings and populations.
14 Forest plots were created to visually assess the results of pooling. Subgroups were created based on subtype of PAH. If a study consisted of patients with different subtypes of PAH and survival data was not given independently, the respective authors were contacted for the data. If the data were still unavailable, the study was excluded from the subgroup analysis. We also conducted a subgroup analysis to examine whether the type of study (prospective/retrospective) impacted the results. χ 2 testing was performed to assess for subgroup differences.
Heterogeneity across studies was evaluated using Higgins I 2 statistic, and a value of I 2 =25% to 50% was considered mild, 50% to 75% as moderate, and >75% as severe. 15 Visual inspection of the funnel plot and Egger regression test was performed to evaluate publication bias. A P value of <0.05 was considered significant in all cases. Given the statistical heterogeneity among the included studies, we conducted moments of methods meta-regression analysis to assess the proportion of variance between the studies explained by study level covariates: study year, age, sample size, and NOS. The index, R2, was used to report the ratio of explained variance to the total variance. The R2 value ranges from 0% to 100%. Meta-regression was only conducted for the IPAH subgroup, as other subgroups had an insufficient number of studies for this analysis. Comprehensive meta-analysis (Version 2; Biostat Inc; Englewood, NJ) was used to conduct the meta-regression. Furthermore, we carried out cumulative meta-analysis for the IPAH subgroup to study temporal trends. This chronological combining of the studies reveals if there is a constancy in the results of consecutive studies and indicates the point at which no additional studies are required because the results continually favor one practice. This technique can also help identify changing trends because of changes in background therapy.
RESULTS
Literature Search Results
The initial search revealed 7524 articles. After applying eligibility criteria, 12 studies were selected for inclusion in the meta-analysis. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The search revealed no randomized controlled trials. The PRIS-MA flowchart (Figure 1 ) summarizes the literature search.
Study Characteristics
The 12 selected studies included 2512 patients (1342 in the anticoagulant arm and 1170 in the control arm). Eight of the studies had a retrospective design, [16] [17] [18] [19] [20] [21] [22] [23] and 4 had a prospective design. [24] [25] [26] [27] The median follow- 16 ) , and risk ratio was calculated and used in this case.
Majority of studies (67%) did not report on cause of death. Among those that did, right heart failure was consistently the primary cause of death, as would be expected in a PAH cohort. Six out of 9 studies in IPAH patients reported the types of concomitant therapies used. All 3 studies on SSc-PAH patients reported the types of concomitant therapies. A pattern was noted, with older (pre-2000) studies using digoxin and diuretics as adjunct therapies and newer studies employing the use of targeted therapies such as prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Baseline characteristics are outlined in Table 1 . 
Findings of Meta-Analysis
Overall, anticoagulation was associated with a statistically significant reduction in mortality compared with controls (HR, 0.73 [0.57-0.93]; P=0.001; I 2 =64%), as displayed in Figure 2 . On stratifying the included studies based on study design (Figure 2) 
CTD-Associated PAH
Four studies reported data in patients with CTD-associated PAH. Three of these (Johnson et al, 23 Preston et al, 27 and 
Drug-Induced PAH
Only one study (Frank et al 19 ) reported data from patients with drug (anorexigen) induced PAH; although it trended toward benefit with anticoagulation, a statistically significant reduction in mortality was not realized (HR, 0.65 [0.41-1.04]; P=0.07).
Meta Regression and Cumulative Meta Analysis
Meta-regression of the 4 covariates (study year, mean age, sample size, and NOS score) showed that the individual models of study year and NOS score explained 26% and 31% of the variance respectively, while age and sample size did not contribute to variance (0%). However, the final model computing all the covariates combined explained 98% of the statistical heterogeneity (T2=0.0026, R2=0.98, Q=30.5, df (4); P<0.001). None of the 4 covariates, that is, study year (P=0.43), mean age (P=0.49), sample size (P=0.43), or NOS (P=0.40), was significantly correlated with the HRs of the included studies. Cumulative meta-analysis revealed a chronological trend towards higher HRs (Figure 4 ).
There appears to be a shifting trend; recent results do not seem to have reached consistency.
Risk of Bias, Publication Bias, and Overall Certainty of Evidence
The studies overall had moderate to good methodological quality ( Table 2) . Asymmetry of the funnel plot suggests publication bias. The vacant quadrant suggests that the missing studies could have shown increased mortality with anticoagulation ( Figure 5 ). Egger regression test confirmed the likely presence of publication bias (P=0.03). As per the Grading of Recommendations, Assessment, Development, and Evaluation approach (Table 3) , the evidence from this meta-analysis warrants a low level of certainty, mainly because of the bias-prone nature of observational studies and the detection of publication bias and heterogeneity.
DISCUSSION
This systematic review and meta-analysis of 2512 PAH patients suggest that in Group 1 PAH, routine use of anticoagulants is associated with a significant decrease in mortality when notable with controls. More importantly, subgroup analyses based on PAH-type revealed important differences. Anticoagulation was associated with decreased mortality in patients with IPAH, whereas anticoagulation increased mortality in SSc-PAH patients. A previous, smaller meta-analysis also suggested an overall improved survival among all PAH patients taking anticoagulants. 28 However, the previous meta-analysis did not stratify the data according to PAH subtype. Our study enhances evidence from the previous review with the addition of 3 more studies, 2 of which (Preston et al 27 and Johnson et al 23 ) had a relatively large sample size, were of high methodological quality, and thus contributed to our meta-analysis in a meaningful way. PAH is a complex disease involving multiple contributory pathways, some of which remain elusive. [29] [30] [31] Numerous studies of PAH pathobiology have shown that thrombotic vascular lesions likely play an important role in PAH. [32] [33] [34] Wagenvoort et al 35, 36 demonstrated thrombosis of small pulmonary arteries as a characteristic histopathologic feature of PAH. Other studies have reported hypercoagulability in patients with severe cases of PAH. 37, 38 Moreover, levels of thrombin are increased in PAH patients, which not only contributes to hypercoagulability but is also a potent growth factor and mitogen that plays a direct role in the uncontrolled vascular proliferation, which features in PAH progression. 5, 39 The use of anticoagulants in PAH patients could potentially counteract thrombosis and hypercoagulability and also mitigate the proliferative effects of thrombin. When early research discoveries were followed by a series of small, observational studies suggesting a potential mortality benefit of anticoagulants in PAH, 17, 25 routine anticoagulation was adopted into the clinical guidelines.
Current ACC guidelines recommend anticoagulation in all Group 1 PAH patients (class IIB recommendation), 7 but this recommendation is extrapolated mainly from data available exclusively in IPAH patients and may not be applicable to all subtypes of PAH. In fact, concerns have been raised that this practice could be potentially dangerous, highlighting that certain subtypes of PAH may have both distinct mechanisms and other clinically relevant processes at play that are not present in IPAH. For example, abnormalities of coagulation factors and impaired fibrinolysis are common findings in IPAH 40 but do not seem to play as major a role in the pathophysiology of SSc-PA. 41 In this context of a sufficiently different pathobiology among PAH subtypes, we decided to stratify the available data according to subtype of PAH. Our systematic search revealed that IPAH was the most studied subtype of PAH, with 9 out of the 12 included studies reporting IPAH data. Despite a recent prospective cohort study that did not show a benefit in survival in IPAH patients receiving anticoagulation, 27 this metaanalysis found that anticoagulation was associated with overall increased survival in IPAH patients. These findings are consistent with several individual cohort studies, including the largest study in this area, the COMPERA study (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension). 24 Our results are in line with current guidelines and support continued use of anticoagulation in IPAH patients. In contrast, Preston et al 27 and Johnson et al 23 showed no increased survival with anticoagulation in these patients. The difference in results between Preston et al 27 and COMPERA is intriguing and not easily reconcilable. However, one explanation could be the presence of potential immortal time bias in the COMPERA study. 6, 42 In COMPERA, patients starting warfarin were compared with patients never on warfarin. The time between inclusion in the registry and initiation of warfarin is defined as immortal time, during which death cannot occur because of the exposure definition. This confers additional survival time to the warfarin group, potentially skewing the analysis in their favor. However, the true existence and extent of immortal time bias in the COMPERA study remain debatable, and its full impact remains unclear. However, the studies conducted by Johnson et al 23 and Preston et al 27 may have inclusion bias. As shown in Table 1 , the usage of other drugs used to treat IPAH was greater in the warfarin group in both the studies, indicating that patients in the warfarin group may have had greater disease severity; consequently, it is possible that this could partly explain why these stud- ies did not show increased survival with anticoagulation. Although the results of our study support the use of anticoagulation in IPAH patients, the inherent risk of bleeding, as well as other contraindications, should be considered before adding it the treatment regimen; moreover, until our findings are confirmed by a prospective, randomized trial, an individualized approach to anticoagulation in IPAH is advisable.
The present meta-analysis showed no improvement in survival with anticoagulant use in patients with CTDassociated PAH. SSc-PAH is much more prevalent than other types of CTD-associated PAH, 43 and only 1 of the 4 studies included patients outside of the SSc-PAH subtype. Given this fact, coupled with the difference in interstudy methodology, a sensitivity analysis was performed by removing this study to examine the effect of anticoagulation solely on patients with SSc-PAH. In contrast to the benefit seen in those with IPAH, we observed that anticoagulation in SSc-PAH was associated with significantly decreased survival. The reasons why anticoagulation in SSc-PAH may be associated with potential for harm is not entirely clear. Although the presence of gastrointestinal vascular lesions may occur more commonly in SSc-PAH than in IPAH, none of the SSc-PAH studies reported an increased occurrence of major gastrointestinal bleeds in those receiving anticoagulants relative to controls. Nonetheless, on the basis of our findings, we would caution against anticoagulant use in SSc-PAH patients until further studies can be performed.
Cumulative meta-analysis revealed a chronological trend towards higher HRs in IPAH patients; that is, reduced difference in survival between the group receiving anticoagulants and the control group. A potential explanation for this finding could be the availability of more effective background therapy for PAH, which was received by both groups. Better survival in both the treatment and control groups could thus have narrowed the benefits of antico- 
Limitations
This systematic review has limitations, mostly related to the methodology and reporting quality of the included studies. Our systematic search did not yield any randomized controlled trials, and therefore, our results are based solely on observational studies. The best available data on this topic continue to be observational studies, which are unable to fully account for confounding factors and limit the conclusiveness of a meta-analysis. Furthermore, the results were subject to considerable heterogeneity, some of which is possibly because of variation in the type of concomitant therapies that participants were receiving, both between the studies themselves, as well as between the 2 groups of patients examined (anticoagulation and controls) in each study. Another limitation was the possibility of publication bias; for instance, smaller studies showing increased mortality with anticoagulants appeared to be missing. This may be because journals are less likely to publish small studies or studies with negative results and authors may be more likely to submit for publication studies with positive results and disregard the negative ones. 44 Finally, most studies did not adjust for the main prognostic variables, including age and sex.
Conclusions
To help reconcile the ongoing debate about the use of anticoagulants in PAH, we pooled results from all available studies, some recent. The meta-analysis shows that anticoagulation appears to benefit IPAH patients, while potentially harmful to those with SSc-PAH. There is a need for clinical trials in this area. Given these findings, an update to existing PAH guidelines should be considered, and advocacy for prospective, randomized clinical trial should continue.
